FierceBiotech 2026-03-04 Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'
FierceBiotech 2026-03-04 Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
FierceBiotech 2026-03-04 Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option
FierceBiotech 2026-03-04 Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset
FierceBiotech 2026-03-03 New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
FierceBiotech 2026-03-03 Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
FierceBiotech 2026-03-03 FDA details rationale for rejecting rare disease gene therapy from Regenxbio
FierceBiotech 2026-03-03 MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
FierceBiotech 2026-03-03 Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
FierceBiotech 2026-03-03 AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal
FierceBiotech 2026-03-03 GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels
FierceBiotech 2026-03-03 HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
FierceBiotech 2026-03-02 Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
FierceBiotech 2026-03-02 TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio